Why Sera Prognostics, Inc.’s (SERA) Stock Is Up 5.43%
As of Wednesday, September 30, Sera Prognostics, Inc.’s SERA share price has surged by 5.43%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Commentary & Analysis
Why Sera Prognostics, Inc.’s (SERA) Stock Is Up 5.18%
As of Monday, August 31, Sera Prognostics, Inc.’s SERA share price has surged by 5.18%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Sera Prognostics, Inc.’s (SERA) Stock Is Down 5.24%
As of Friday, August 21, Sera Prognostics, Inc.’s SERA share price has dipped by 5.24%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Sera Prognostics, Inc.’s (SERA) Stock Is Up 5.70%
As of Wednesday, August 19, Sera Prognostics, Inc.’s SERA share price has surged by 5.70%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Sera Prognostics, Inc.’s (SERA) Stock Is Down 5.80%
As of Monday, August 10, Sera Prognostics, Inc.’s SERA share price has dipped by 5.80%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | SERA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $80.5 | $250.6 | 20% |
|
| Shares Out (Mil) | 50.5 | 54.0 | 48% |
|
| Institutional Ownership | 88.3% | 93.1% | 56% |
|
| Float (Mil) | 27.7 | 41.4 | 34% |
|
| Beta | 0.98 | 0.95 | 59% |
|
| Avg Daily Volume (000s) | 18 | 720 | 20% |
|
| Price Change (52-week) |
(33.3%) | 49.4% | 26% |
|
| Growth | SERA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (10.0%) | (10.2%) | 29% |
|
| EPS (5yr) | 44.5% | 15.7% | 91 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 14.9% | (15.7%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.140) | ($0.658) | ($0.535) | |
| Month Ago EPS | ($0.140) | ($0.658) | ($0.535) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.167) | ($0.680) | ($0.577) | |
| Year/Year Chg | (22.7%) | (1.8%) | (27.6%) | |
| Financials | SERA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $36 | na |
|
| Net Income (TTM) (Mil) | ($33) | ($44) | 20% |
|
| EPS (TTM) | ($0.664) | ($1.600) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($28) | ($33) | 13% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $2 | 41% |
|
| Long-Term Debt (Q1) (Mil) | $3 | $4 | 22% |
|
| Enterprise Value (Q1) (Mil) | $-0 | $174 | 3% |
|
| Valuation | SERA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.35 | 2.41 | 37% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SERA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (150.0%) | 67.3% | 2% |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (33.5%) | (47.7%) | 16% |
|
| ROE | (45.0%) | (55.0%) | 16% |
|
| Liabilities to Assets | 31.5% | 29.3% | 22% |
|
| F-Score | 2 | 3 | 7% |
|
Passing Stock Screens
As of 10/1/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Insider Net Purchases Screen
Factors: Other
A stock screen designed to find small-cap companies that have more stock purchased than sold by insiders.
| Performance Since Inception: | -2.8% |
| +/- S&P 500: | -10.3 |
